World Library  
Flag as Inappropriate
Email this Article

Autoimmune lymphoproliferative syndrome

Article Id: WHEBN0005812984
Reproduction Date:

Title: Autoimmune lymphoproliferative syndrome  
Author: World Heritage Encyclopedia
Language: English
Subject: Hirschsprung's disease, Congenital hypothyroidism, Hypohidrotic ectodermal dysplasia, Index of molecular biology articles, Fas ligand
Collection: Lymphocytic Immune System Disorders, Rasopathies
Publisher: World Heritage Encyclopedia

Autoimmune lymphoproliferative syndrome

Autoimmune lymphoproliferative syndrome
Classification and external resources
ICD-9-CM 279.41
OMIM 601859 603909
DiseasesDB 33425 33424

Autoimmune lymphoproliferative syndrome (ALPS), also known as Canale-Smith syndrome,[1] is a form of lymphoproliferative disorder (LPDs). It affects lymphocyte apoptosis.[2] It is a RASopathy.

It is a rare genetic disorder of abnormal lymphocyte survival caused by defective Fas mediated apoptosis.[3] Normally, after infectious insult, the immune system down-regulates by increasing Fas expression on activated B and T lymphocytes and Fas-ligand on activated T lymphocytes. Fas and Fas-ligand interact to trigger the caspase cascade, leading to cell apoptosis. Patients with ALPS have a defect in this apoptotic pathway, leading to chronic non-malignant lymphoproliferation, autoimmune disease, and secondary cancers.[4]


  • Genetics 1
  • Clinical manifestations 2
  • Laboratory manifestations 3
  • Classification 4
  • Diagnostic algorithm 5
  • Treatment 6
  • References 7


This condition is usually caused by mutations in the FAS gene. Rarely cases due to mutations in other genes including the FAS ligand gene have been reported.[5]

Clinical manifestations

All people with ALPS have signs of lymphoproliferation, which makes it the most common clinical manifestation of the disease. The increased proliferation of lymphoid cells can cause the size of lymphoid organs such as the lymph nodes and spleen to increase (lymphadenopathy and splenomegaly, present in respectively over 90% and over 80% of patients). The liver is enlarged (hepatomegaly in 30 - 40% of patients.

Autoimmune disease is the second most common clinical manifestation and one that most often requires treatment. Autoimmune cytopenias: Most common. Can be mild to very severe. Can be intermittent or chronic.[6] These include: Autoimmune hemolytic anemia, Autoimmune neutropenia, Autoimmune thrombocytopenia.

Other signs can affect organ systems similar to systemic lupus erythematosus (least common, affecting <5% of patients) Symptoms of the nervous system include: Autoimmune cerebellar ataxia; Guillain-Barre syndrome; transverse myelitis. Gastrointestinal signs like Autoimmune esophagitis, gastritis, colitis, hepatitis, pancreatitis can be found or (Dermatologic) Urticaria, (Pulmonary) bronchiolitis obliterans, (Renal) Autoimmune glomerulonephritis, nephrotic syndrome.

Another sign are cancers such as Hodgkin and non-Hodgkin lymphomas which appear to be increased,[1] possibly due to Epstein-Barr virus-encoded RNA-positivity. Some carcinomas may be occur. Unaffected family members with genetic mutations are also at an increased risk of developing cancer.

Laboratory manifestations

  • Elevated peripheral blood Double Negative T cells (DNTs)[7]
    • Required for diagnosis
    • Immunophenotype: CD3+/CD4-/CD8-/TCRalpha/beta+
    • Measured by flow cytometry: Normal values <2.5% total T cells; <1% of total lymphocytes in peripheral blood
    • Marked elevations >5% virtually pathognomonic for ALPS
    • Mild elevations also found in other autoimmune diseases
    • Thought to be cytotoxic T lymphocytes that have lost CD8 expression
    • Unknown if driver of disease or epiphenomenon
    • May be falsely elevated in setting of lymphopenia or falsely decreased with immunosuppressive treatment
  • Defective in vitro Fas mediated apoptosis
    • Required for diagnosis under old definition. Now can be used to make diagnosis; however, not required to make diagnosis.
    • Time and labor-intensive assay.
    • T cells from patient and normal control supported in culture for >10 days with mitogen stimulation and IL-2 expansion and then exposed to anti-Fas IgM monoclonal antibody
    • ALPS patient T cells: Do not die with anti-Fas monoclonal antibody exposure. Normal T cells from unaffected patient do.
    • False negative in somatic Fas variant ALPS and FasL variant ALPS
  • Genetic mutations in ALPS causative genes (see below)
  • Biomarkers[8][9]
  • Autoantibodies: Non-specific. Can have antibodies to blood cells (DAT, anti-neutrophil, anti-platelet). Also, can have positive ANA, RF, ANCA.


2003 nomenclature[11]

Revised nomenclature (2010)[12]

  • ALPS-FAS: Fas. Germline FAS mutations. 70% of patients. Autosomal dominant. Dominant negative and haploinsufficient mutations described.[13]
  • ALPS-sFAS: Fas. Somatic FAS mutations in DNT compartment.[14] 10% of patients
  • ALPS-FASL: Fas ligand. Germline FASL mutations. 3 reported cases
  • ALPS-CASP10: Caspase 10. Germline CASP10 mutation. 2% of patients
  • ALPS-U: Undefined. 20% of patients
  • CEDS: Caspase 8 deficiency state. No longer considered a subtype of ALPS but distinct disorder
  • RALD: NRAS, KRAS. Somatic mutations in NRAS and KRAS in lympocyte compartment. No longer considered a subtype of ALPS but distinct disesase

Diagnostic algorithm

The old diagnostic criteria for the illness included:[11] Chronic non-malignant lymphoproliferation, elevated peripheral blood DNTs and defective in vitro Fas mediated apoptosis.

The new criteria[12] requires chronic non-malignant lymphoproliferation (>6 months lymphadenopathy and/or splenomegaly), elevated peripheral blood DNTs. A primary accessory in diagnosis is defective in vitro Fas mediated apoptosis and somatic or germline mutation in ALPS causative gene (FAS, FASL, CASP10).

The secondary accessory in diagnosis are elevated biomarkers (Plasma sFASL >200pg/ml, Plasma IL-10 >20pg/ml, Plasma or serum vitamin B12 >1500 ng/L, Plasma IL-18 >500pg/ml) and immunohistochemical findings on biopsy consistent with ALPS as determined by an experienced hematopathologist. Also another sign is autoimmune cytopenias and polyclonal hypergammaglobulinemia and a family history of ALPS or non-malignant lymphoproliferation.

A definitive diagnosis is chronic non-malignant lymphoproliferation and/or elevated peripheral blood DNTs plus one primary accessory criteria. A probable diagnosis is the same but with one secondary accessory criteria.


Treatment is most commonly directed at autoimmune disease and may be needed to treat bulky lymphoproliferation. First line therapies include corticosteroids (very active but toxic with chronic use), and IVIgG, which are not as effective as in other immune cytopenia syndromes.

Second line therapies include: mycophenolate mofetil (cellcept)[15] which inactivates inosine monophosphate, most studied in clinical trials with responses varying (relapse, resolution, partial response). It does not affect lymphoproliferation or reduce DNTs, with no drug-drug interactions. This treatment is commonly used agent in patients who require chronic treatment based on tolerance and efficacy. It may cause hypogammaglobulinemia (transient) requiring IVIgG replacement.

Sirolimus (rapamycin, rapamune) which is a mTOR (mammalian target of rapamycin) inhibitor[16] can be active in most patients and can in some cases lead to complete or near-complete resolution of autoimmune disease (>90%)[17][18] With this treatment most patients have complete resolution of lymphoproliferation, including lymphadenopathy and splenomegaly (>90%) and have elimination of peripheral blood DNTs. Sirolimus may not be as immune suppressive in normal lymphocytes as other agents. Some patients have had improvement in immune function with transition from cellcept to rapamycin[19] and it has not been reported to cause hypogammaglobulinemia. Hypothetically, Sirolimus may have lower risk of secondary cancers as opposed to other immune suppressants and requires therapeutic drug monitoring. It is the second most commonly used agent in patients that require chronic therapy. It is mostly well tolerated (though side effects include mucositis, diarrhea, hyperlipidemia, delayed wound healing) with drug-drug interactions. It has better activity against autoimmune disease and lymphoproliferation than mycophenolate mofetil and other drugs; however, sirolimus requires therapeutic drug monitoring and can cause mucositis. A risk with any agent in pre-cancerous syndrome as immune suppression can decreased tumor immunosurvellence. Its mTOR inhibitors active against lymphomas, especially EBV+ lymphomas. The Goal serum trough is 5-15 ng/ml and can consider PCP prophylaxis but usually not needed.

Other treatments may include drugs like Fansidar,[20][21] mercaptopurine: More commonly used in Europe. Another is rituximab but this can cause lifelong hypogammaglobulinemia[22] and a splenectomy but there is a >30% risk of pneumococcal sepsis even with vaccination and antibiotic prophylaxis[23][24]


  1. ^ a b Straus SE, Jaffe ES, Puck JM et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood. 2001 Jul 1;98(1):194-200. PMID 11418480
  2. ^ Fleisher, Thomas A. (2007). "The autoimmune lymphoproliferative syndrome: An experiment of nature involving lymphocyte apoptosis". Immunologic Research 40 (1): 87–92.  
  3. ^ Rao, V. Koneti; Straus, Stephen E. (2006). "Causes and consequences of the autoimmune lymphoproliferative syndrome". Hematology 11 (1): 15–23.  
  4. ^ Teachey, David T.; Seif, Alix E.; Grupp, Stephan A. (2010). "Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS)". British Journal of Haematology 148 (2): 205–16.  
  5. ^ Magerus-Chatinet A, Stolzenberg MC, Lanzarotti N, Neven B, Daussy C, Picard C, Neveux N, Desai M, Rao M, Ghosh K, Madkaikar M, Fischer A, Rieux-Laucat F (2012) Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation. J Allergy Clin Immunol
  6. ^ Teachey, David T.; Manno, Catherine S.; Axsom, Kelly M.; Andrews, Timothy; Choi, John K.; Greenbaum, Barbara H.; McMann, Joseph M.; Sullivan, Kathleen E.; et al. (2005). "Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS)". Blood 105 (6): 2443–8.  
  7. ^ Bleesing, Jack J.H.; Brown, Margaret R.; Novicio, Cynthia; Guarraia, David; Dale, Janet K.; Straus, Stephen E.; Fleisher, Thomas A. (2002). "A Composite Picture of TcRα/β+ CD4CD8 T Cells (α/β-DNTCs) in Humans with Autoimmune Lymphoproliferative Syndrome". Clinical Immunology 104 (1): 21–30.  
  8. ^ Magerus-Chatinet, Aude; Stolzenberg, Marie-Claude; Loffredo, Maria S.; Neven, Bénédicte; Schaffner, Catherine; Ducrot, Nicolas; Arkwright, Peter D.; Bader-Meunier, Brigitte; et al. (2009). "FAS-L, IL-10, and double-negative CD4CD8 TCR α/β+ T cells are reliable markers of autoimmune lymphoproliferative syndrome (ALPS) associated with FAS loss of function". Blood 113 (13): 3027–30.  
  9. ^ Caminha, Iusta; Fleisher, Thomas A.; Hornung, Ronald L.; Dale, Janet K.; Niemela, Julie E.; Price, Susan; Davis, Joie; Perkins, Katie; et al. (2010). "Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome". Journal of Allergy and Clinical Immunology 125 (4): 946–949.e6.  
  10. ^ Seif, A. E.; Manno, C. S.; Sheen, C.; Grupp, S. A.; Teachey, D. T. (2010). "Identifying autoimmune lymphoproliferative syndrome in children with Evans syndrome: A multi-institutional study". Blood 115 (11): 2142–5.  
  11. ^ a b Sneller, Michael C.; Dale, Janet K.; Straus, Stephen E. (2003). "Autoimmune lymphoproliferative syndrome". Current Opinion in Rheumatology 15 (4): 417–21.  
  12. ^ a b Oliveira, J. B.; Bleesing, J. J.; Dianzani, U.; Fleisher, T. A.; Jaffe, E. S.; Lenardo, M. J.; Rieux-Laucat, F.; Siegel, R. M.; et al. (2010). "Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): Report from the 2009 NIH International Workshop". Blood 116 (14): e35–40.  
  13. ^ Kuehn, H. S.; Caminha, I.; Niemela, J. E.; Rao, V. K.; Davis, J.; Fleisher, T. A.; Oliveira, J. B. (2011). "FAS Haploinsufficiency is a Common Disease Mechanism in the Human Autoimmune Lymphoproliferative Syndrome". The Journal of Immunology 186 (10): 6035–43.  
  14. ^ Holzelova, Eliska; Vonarbourg, Cédric; Stolzenberg, Marie-Claude; Arkwright, Peter D.; Selz, Françoise; Prieur, Anne-Marie; Blanche, Stéphane; Bartunkova, Jirina; et al. (2004). "Autoimmune Lymphoproliferative Syndrome with SomaticFasMutations". New England Journal of Medicine 351 (14): 1409–18.  
  15. ^ Koneti Rao, V.; Dugan, Faith; Dale, Janet K.; Davis, Joie; Tretler, Jean; Hurley, John K.; Fleisher, Thomas; Puck, Jennifer; Straus, Stephen E. (2005). "Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome". British Journal of Haematology 129 (4): 534–8.  
  16. ^ Teachey, D. T.; Obzut, DA; Axsom, K; Choi, JK; Goldsmith, KC; Hall, J; Hulitt, J; Manno, CS; et al. (2006). "Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)". Blood 108 (6): 1965–71.  
  17. ^ Teachey, David T.; Greiner, Robert; Seif, Alix; Attiyeh, Edward; Bleesing, Jack; Choi, John; Manno, Catherine; Rappaport, Eric; et al. (2009). "Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome". British Journal of Haematology 145 (1): 101–6.  
  18. ^ Janić, MD; Brasanac, CD; Janković, JS; Dokmanović, BL; Krstovski, RN; Kraguljac Kurtović, JN (2009). "Rapid regression of lymphadenopathy upon rapamycin treatment in a child with autoimmune lymphoproliferative syndrome". Pediatric blood & cancer 53 (6): 1117–9.  
  19. ^ Teachey, David T. (2011). "Autoimmune Lymphoproliferative Syndrome: New Approaches to Diagnosis and Management". Clinical Advances in Hematology & Oncology 9 (3): 233–5.  
  20. ^ Van Der Werff Ten Bosch, Jutte; Schotte, Peter; Ferster, Alice; Azzi, Nadira; Boehler, Thomas; Laurey, Genevieve; Arola, Mikko; Demanet, Christian; et al. (2002). "Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: Preliminary results of a clinical cohort study and molecular observations". British Journal of Haematology 117 (1): 176–88.  
  21. ^ Rao, V. Koneti; Dowdell, Kennichi C.; Dale, Janet K.; Dugan, Faith; Pesnicak, Lesley; Bi, Lilia L.; Hoffmann, Victoria; Penzak, Scott; et al. (2007). "Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome". American Journal of Hematology 82 (12): 1049–55.  
  22. ^ Rao, V. Koneti; Price, Susan; Perkins, Katie; Aldridge, Patricia; Tretler, Jean; Davis, Joie; Dale, Janet K.; Gill, Fred; et al. (2009). "Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS)". Pediatric Blood & Cancer 52 (7): 847–52.  
  23. ^ Rao, V. K.; Oliveira, J. B. (2011). "How I treat autoimmune lymphoproliferative syndrome". Blood 118 (22): 5741–51.  
  24. ^ Neven, Bénédicte; Magerus-Chatinet, Aude; Florkin, Benoit; Gobert, Delphine; Lambotte, Olivier; De Somer, Lien; Lanzarotti, Nina; Stolzenberg, Marie-Claude; et al. (2011). "A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation". Blood 118 (18): 4798–807.  
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.